Three-Year Agreement Provides Accuray With Access to More Than 3,000 Member Hospitals for the CyberKnife(R) M6(TM) and TomoTherapy(R) HDA(TM) Systems
SUNNYVALE, Calif., Sept. 9, 2014 (GLOBE NEWSWIRE) -- Accuray Incorporated (Nasdaq:ARAY) announced today that it has been awarded a new, exclusive three-year group purchasing agreement with Premier, Inc., covering the CyberKnife® M6™ and TomoTherapy® HDA™ product portfolios. The Accuray and Premier partnership brings together two companies committed to driving improved patient care through meaningful technical innovation.
"Our goal is to help healthcare providers to offer the best treatment option for their patients. The Premier agreement is important because it enables us to partner with a large sales force that has long-standing relationships with hospital-based clinicians and administrators to significantly increase visibility of the CyberKnife and TomoTherapy Systems," said Kelly Londy, executive vice president and chief commercial officer of Accuray.
Premier has one of the nation's largest group purchasing organizations (GPOs). Under the new contract, Accuray's precise, leading-edge, clinically proven tumor treatments became available starting on September 1, 2014, to Premier member hospitals and providers. Premier unites an alliance of more than 3,000 hospitals and 110,000 other providers, including oncology centers. In addition, the contract provides Accuray with access to key Premier integrated delivery network partners, where Accuray has had limited historical business presence.
"We believe the Premier agreement will provide improved deal visibility to radiation equipment purchasing decisions earlier in the process and, ultimately, result in new opportunities for Accuray equipment and services," said Joshua H. Levine, president and chief executive officer of Accuray. "The partnership also validates our focus on service excellence and technology performance, and demonstrates the confidence the radiation oncology community has in the unique benefits of the CyberKnife and TomoTherapy Systems."
About Premier, Inc.
Premier, Inc. is a leading healthcare improvement company, uniting an alliance of approximately 3,000 U.S. hospitals and 110,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and advisory and other services, Premier enables better care and outcomes at a lower cost. Premier, a Malcolm Baldrige National Quality Award recipient, plays a critical role in the rapidly evolving healthcare industry, collaborating with members to co-develop long-term innovations that reinvent and improve the way care is delivered to patients nationwide. Headquartered in Charlotte, N.C., Premier is passionate about transforming American healthcare. Please visit Premier's news and investor sites on www.premierinc.com; as well as Twitter, Facebook, LinkedIn, YouTube, Instagram, Foursquare and Premier's blog for more information about the company.
About the CyberKnife® and TomoTherapy® Systems
The Accuray CyberKnife M6™ Series and TomoTherapy H™ Series treatment solutions cover the entire spectrum of radiation therapy needs. The CyberKnife M6 Series enables precise, high-quality, high-dose distributions to be confidently delivered to the patient with extreme accuracy over a minimum number of treatments, reducing side effects and preserving patients' quality of life. The CyberKnife System is the only robotic full-body radiosurgery system available today. The TomoTherapy H Series efficiently enables physicians to customize treatment plans for the entire range of radiation therapy patients and disease types. Its innovative design enables treatment plans to be delivered with integrated, daily CT image guidance, enhancing accuracy and delivering highly precise, intensity-modulated radiation for optimal sparing of healthy tissue and critical structures.
Further information on Accuray, the CyberKnife and TomoTherapy Systems is available at www.accuray.com.
About Accuray
Accuray Incorporated (Nasdaq:ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to market access, future orders and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 29, 2014, and our other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
CONTACT: Beth Kaplan
Accuray
+1 (408) 789-4426
bkaplan@accuray.com
Kirsten Fallon
MSLGROUP in Boston
+1 (781) 684-0770
Kirsten.Fallon@MSLGROUP.com
Accuray
